LTFS
TVTX icon

Ladenburg Thalmann Financial Services’s Travere Therapeutics TVTX Stock Holding History

Ladenburg Thalmann Financial Services’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-191
Closed -$4K – 5407
2019
Q1 		$4K Buy
191
+66
+53% +$1.46K ﹤0.01% 4761
2018
Q4 		$3K Buy
+125
New +$3.11K ﹤0.01% 4806

Other funds holding TVTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Ladenburg Thalmann Financial Services's TVTX Position: Q2 2019 in Review

Ladenburg Thalmann Financial Services sold out of Travere Therapeutics (TVTX) in Q2 2019, closing a stake of 191 shares — an estimated $4K sold.

Ladenburg Thalmann Financial Services first reported a position in TVTX in Q4 2018 and held it in 2 quarters. The position peaked at $4K in Q1 2019. 122 funds tracked by Wall St. Rank hold TVTX as of Q2 2019.

  • Ladenburg Thalmann Financial Services reported no remaining Travere Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Ladenburg Thalmann Financial Services sold 191 Travere Therapeutics shares in Q2 2019, an estimated $4K.
  • Ladenburg Thalmann Financial Services first reported a position in Travere Therapeutics in Q4 2018 and held it in 2 quarters.
  • Ladenburg Thalmann Financial Services's Travere Therapeutics position peaked at $4K in Q1 2019.
  • 122 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2019.

Based on Ladenburg Thalmann Financial Services's 13F filing for Q2 2019, filed 15 Aug 2019.